Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial

JAMA Oncol. 2023 Feb 1;9(2):277. doi: 10.1001/jamaoncol.2022.6144.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Fluorouracil / therapeutic use
  • Humans
  • Neoadjuvant Therapy*
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / radiotherapy

Substances

  • Fluorouracil